aibioChina Resources Pharmaceutical issues RMB800 million third tranche of notes
Tickers 3320
A wholly owned subsidiary completed the third 2026 tranche of medium term notes, RMB800 million at 1.45% per annum over three years.
Key facts
- Company
- China Resources Pharmaceutical Group Ltd. (HKEX: 3320)
- News type
- Debt Financing
- Primary source
- China Resources Pharmaceutical Group Limited announcement (2026-10-23)
China Resources Pharmaceutical Group Limited said on October 23, 2026 that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, completed the issuance of the third tranche of medium term notes for 2026 in the PRC. The announcement refers to earlier announcements dated 29 May 2026, 22 July 2026 and 29 July 2026 about the proposed issuance and the first and second tranches.
The third tranche was issued in a principal amount of RMB800 million, with a term of three years and a coupon rate of 1.45% per annum.
The net proceeds will be used for repayment of interest-bearing debts and other purposes that comply with applicable laws and regulations.
The announcement names no placement agent, underwriter or advisor for the notes. Shareholders and potential investors were told to take care when dealing in the company's securities.